Last Update: Oct 30, 2026
Understanding Drug Utilisation, Treatment Patterns, Clinical Outcomes, and Profile of the Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan for the Treatment of Metastatic Prostate Cancer: a Multicountry, AI-powered Registry (PULSE)
ClinicalTrials.gov Identifier:
NCT07484269
Novartis Reference Number:CAAA617A02001
See if you Pre-qualify
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

The primary objective of the study is to describe real-world drug utilisation of lutetium (177Lu) vipivotide tetraxetan among patients with metastatic prostate cancer This study is planned as a multicountry, non-interventional, longitudinal AI-enhanced digital registry that will leverage advanced data extraction technologies to efficiently generate RWD.

The primary objective of the study is to describe real-world drug utilisation of lutetium (177Lu) vipivotide tetraxetan among patients with metastatic prostate cancer.

Metastatic Prostate Cancer
Recruiting
753
Sep 30, 2026
Jul 31, 2031
Male
- (Child, Adult, Older Adult)

Eligibility Criteria

Inclusion criteria:

Age ≥ 18 years at index date

* Diagnosis of mPC
* PSMA positive
* Received at least one dose of lutetium (177Lu) vipivotide tetraxetan on or after mPC diagnosis date

Exclusion criterion:

• Current or prior participation in an investigational study within the 30-day period immediately prior to and including the index date, or within five half-lives of the investigational product (whichever is longer)

Novartis Investigative SIte

Recruiting

Basel,4056,Switzerland

Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

Novartis Pharmaceuticals

+41613241111